Form 4 for BDTX Black Diamond Therapeutics, Inc.
Accepted 2026-09-21 17:45:30 ET · period of report 2026-09-18 · accession 0001193125-26-396868 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-21 17:45 | 2026-09-18 | BDTX | Behbahani Ali | Dir | A - Grant | $1.93 | +7,707 | 110.2K | +8% | +$14.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-18 | A | A | 7,707 | $1.93 | 110,236 | D | — | — | (F1) These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. (F2) The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026. |